OncoSec: Jumps on FDA nod to start testing COVID-19 vaccine candidate

OncoSec Medical Incorporated

29/10/2020 13:31

** Immunotherapy developer's shares  ONCS.O  up 8% at $3.91
premarket
    ** Receives U.S. FDA nod to start early-stage trial to test
its COVID-19 vaccine candidate, CORVax12  urn:newsml:reuters.com:*:nPn8H3kZwa
    ** "We believe that CORVax12 may also be able to protect
those at higher risk for complications from the coronavirus,
including cancer, transplant and elderly patients," says ONCS 
    ** Stock has more than doubled YTD

 (Reporting by Trisha Roy in Bengaluru)
 ((Trisha.Roy@thomsonreuters.com; within U.S. +1 646 223 8780,
outside U.S. +91 80 6182 3635;))